We are a stem cell focused CDMO.
Magle Biopharma, a proud member of the renowned Magle Group, is based in Sweden and is a leading Contract Development and Manufacturing Organization (CDMO). We specialize in the development and production of stem cell-based therapies for both investigational and GMP use.
With expertise, cutting-edge facilities, and a commitment to excellence, we provide comprehensive support to ensure the success of your therapeutic innovations from inception to market. At Magle Biopharma, we leverage our deep industry knowledge, innovative technologies, and robust processes to deliver unparalleled results.

About Magle Group
Magle AB (formed in 1995 as a pure development company) acquired Chemoswed AB (formed in 1944 as a manufacturing company) in 2016 before merging the companies in 2017 to form Magle Chemoswed. In 2019, Adroit Science AB was acquired to increase the development services segment. In 2021, PharmaCept GmbH was acquired as a first step to develop a sales and marketing organization for DSM products. In 2024 Magle Group welcomed Magle Biopolymers - a CDMO part of the group focusing on Dextran technology, and Magle BioPharma - a stem cell based CDMO.
Already working at Magle Group?
Let’s recruit together and find your next colleague.